- Home
- CERO vs SXTP Comparison
CERO vs SXTP Comparison
Compare CERO & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- SXTP
- Stock Information
- Founded
- CERO 2017
- SXTP 2010
- Country
- CERO United States
- SXTP United States
- Employees
- CERO 8
- SXTP N/A
- Industry
- CERO
- SXTP Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- SXTP Health Care
- Exchange
- CERO Nasdaq
- SXTP Nasdaq
- Market Cap
- CERO 3.7M
- SXTP 3.5M
- IPO Year
- CERO N/A
- SXTP 2023
- Fundamental
- Price
- CERO $0.45
- SXTP $2.92
- Analyst Decision
- CERO Buy
- SXTP Buy
- Analyst Count
- CERO 2
- SXTP 2
- Target Price
- CERO $3.00
- SXTP $7.00
- AVG Volume (30 Days)
- CERO 993.4K
- SXTP 271.9K
- Earning Date
- CERO 05-15-2025
- SXTP 05-15-2025
- Dividend Yield
- CERO N/A
- SXTP N/A
- EPS Growth
- CERO N/A
- SXTP N/A
- EPS
- CERO N/A
- SXTP N/A
- Revenue
- CERO N/A
- SXTP $802,323.00
- Revenue This Year
- CERO N/A
- SXTP $95.50
- Revenue Next Year
- CERO N/A
- SXTP $80.78
- P/E Ratio
- CERO N/A
- SXTP N/A
- Revenue Growth
- CERO N/A
- SXTP 118.37
- 52 Week Low
- CERO $0.40
- SXTP $1.41
- 52 Week High
- CERO $102.00
- SXTP $35.99
- Technical
- Relative Strength Index (RSI)
- CERO 35.19
- SXTP 59.68
- Support Level
- CERO $0.42
- SXTP $2.60
- Resistance Level
- CERO $0.50
- SXTP $3.67
- Average True Range (ATR)
- CERO 0.05
- SXTP 0.31
- MACD
- CERO 0.00
- SXTP 0.08
- Stochastic Oscillator
- CERO 24.77
- SXTP 56.52
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.